Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00438321 · ClinicalTrials.gov registry record · Phase 1
Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT00438321: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00438321 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00438321, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of the study is to examine the effect of testosterone treatment on insulin in men with the metabolic syndrome with testosterone levels at or below the lower end of the normal range.
Interventions
- OTHER Placebo
- DRUG Zoladex
- DRUG Testosterone gel
- DRUG Anastrozole Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-02-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00438321
The ClinicalTrials.gov registry entry for NCT00438321 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00438321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00438321 about?
NCT00438321 is a clinical study titled "Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome". The purpose of the study is to examine the effect of testosterone treatment on insulin in men with the metabolic syndrome with testosterone levels at or below the lower end of the normal range.
What is the current status of trial NCT00438321?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2006-09. Estimated completion is 2010-02-26.
What interventions are being tested in trial NCT00438321?
The interventions under investigation include: Placebo (OTHER), Zoladex (DRUG), Testosterone gel (DRUG), Anastrozole Pill (DRUG).
Who is sponsoring clinical trial NCT00438321?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.